News Related to APG-777

Related coverage linked through entity extraction aliases.

Apogee Therapeutics to Present Phase 2 APEX Part B Data as Fund Lifts Stake to $93 Million

May 27, 2026

Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.

AAD 2026 and pipeline updates highlight new atopic dermatitis treatment data

Apr 21, 2026

Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.